


Please type a plus sign (+) inside this box →

PTO/SB/05 AF (10-96) 10/96  
Applicable or use through 10/31/99. OMB #0510-003 EUS  
U.S. DEPARTMENT OF COMMERCE  
Information contained on this form is neither  
copyrighted nor trademarked.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Sheet 1 of 1 Attorney Docket Number 180/95 PCT/US

***Complete if Known***

TECH CENTER 160/2000

Application Number	09/555,349
Filing Date	05/26/2000
First Named Inventor	Thomas F. Tedder
Group Art Unit	
Examiner Name	
Attorney Docket Number	180/95 PCT/US

## U.S. PATENT DOCUMENTS


## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	6/21/01
-----------------------	-------------------------------------------------------------------------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

RECEIVED

Application Number	09/555,349
Filing Date	05/26/2000
First Named Inventor	Thomas F. Tedder
Group Art Unit	
Examiner Name	TECH CENTER 1600/2000
Attorney Docket Number	180/95 PCT/US

DEC 15 2000

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
X	C1	BOHLEN ET AL., "Cytolysis of Leukemic B-Cells by T-Cells Activated via Two Bispecific Antibodies," <i>Cancer Research</i> , p. 4310-4314, (September 15, 1993).
	C2	BURNETT ET AL., "Human Monoclonal Antibodies to Defined Antigens," <i>Human Hybridomas and Mab</i> , Plenum Press, p. 113-133, (1985).
	C3	BRINK ET AL., "Immunoglobulin M and D Antigen Receptors are Both Capable of Mediating B Lymphocyte Activation, Deletion, to Energy After Interaction with Specific Antigen," <i>J. Exp. Med.</i> , p. 991-1005, (October, 1992).
	C4	SATO ET AL., "CD19 Regulates B Lymphocyte Signaling Thresholds Critical for the Development of B-1 Lineage Cells and Autoimmunity," <i>J. Immunology</i> , Vol. 157, p. 4371-4378, (1996).
	C5	ZHOU ET AL., "Tissue-Specific Expression of the Human CD19 Gene in Transgenic Mice Inhibits Antigen-Independent B-Lymphocyte Development," <i>Molecular and Cellular Biology</i> , Vol. 14 (No. 6), p. 3884-3894, (June, 1994).
	C6	PCT International Search Report dated 02 March 1999 for corresponding PCT application number PCT/US98/25253.
X	C7	TEDDER ET AL., "The CD19-CD21 Complex Regulates Signal Transduction Thresholds Governing Humoral Immunity and Autoimmunity," <i>Immunity</i> , Vol. 6, p. 107-118, (February, 1997).

Examiner Signature

Date Considered

6/26/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.